Skip to main navigation
logo

Investor Relations

  • Overview
  • News & Events
    • News Releases
    • Scientific Conferences
    • Investor Calendar
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Corporate Governance
    • Governance Documents
    • Management
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Annual Reports & Proxies
    • Quarterly Results
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR

Event Details

Key Opinion Leader Event

Jun 9, 2021

Galecto will host a key opinion leader event to discuss the current treatment landscape and unmet clinical need for myelofibrosis, as well as the potential for GB2064, Galecto’s LOXL2 inhibitor that is expected to enter a phase 2 trial in the current quarter.

Listen to webcast

Supporting Materials

Galecto Expert Perspectives: Myelofibrosis Treatment Landscape Current and Potential Future Treatments Presentation 2 MB

Site - Investor Tools

  • Email Alerts
  • Print Page
  • RSS Feeds
  • Contact IR

© 2023 Galecto All rights reserved.

  • Cookies
  • Privacy Policy